FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why

  • The FDA has placed a partial clinical hold on Nuvation Bio Inc's NUVB Phase 1 dose-escalation study of NUV-422 in solid tumors.
  • The company's Phase 1 trial began enrolling patients in December 2020 and, in recent months, was exploring higher doses to define a maximum tolerated dose. 
  • Following the emergence of uveitis, a form of inflammation in the eye, in certain patients receiving NUV-422, the company paused the enrollment of new patients to assess these adverse events further. 
  • Also Read: FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors.
  • While the partial hold is in place, no new patients will be enrolled in the NUV-422 program, although current study participants may continue to be treated in the Phase 1 study.
  • The company says that with $737.7 million in cash, it is well-positioned to continue developing all of its internal product candidates.
  • The company will provide updates on the direction of the NUV-422 program after it has completed its internal risk-benefit analysis, which will factor in feedback from FDA.
  • Price Action: NUVB shares are down 7.04% at $3.88 during the premarket session on the last check Monday.

Posted In: Briefswhy it's movingBiotechNewsPenny StocksHealth CareSmall CapFDAMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.